As shown in Fig. 3A and B, tumor-bearing mice treated with cisplatin followed by CpG and PADRE generated the highest number of PADRE-specific IFN-γ+ CD4+ T cells systemically compared to all other treatment groups. This evidence concerns the gene CD4 and neoplasm.